CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release Syndrome in CAR T-cell Therapy
CytoAgents has received approval from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application in oncology.
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA). This clearance enables the initiation of a U.S. Phase 1b/2a clinical trial under its Investigational New Drug (IND) application for the therapeutic, CTO1681, to treat CRS in lymphoma patients receiving CAR T-Cell Therapy. This is an area of great unmet medical need as the majority of patients undergoing CAR T treatment for their cancer experience CRS and associated neurotoxicity.
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage therapeutics company developing a safe, effective treatment (CTO1681) for Cytokine Release Syndrome (CRS), today announced that it has strengthened its leadership team with the appointment of Arthur P. Bertolino MD, PhD, MBA, as Chief Medical Officer. Dr. Bertolino is a seasoned senior pharmaceuticals executive who has led clinical development and business growth for early-stage biotechnology as well as mid-sized and large pharmaceutical companies. Through extensive domestic and international management and drug development experience, including C-level roles in pharmaceuticals and boutique biotechnology, Dr. Bertolino combines science, medicine, and business administration, with leadership acumen and drive to efficiently deliver high-value pharmaceuticals.
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical stage biotechnology company, announced today that its lead drug candidate, GP1681, has successfully completed Phase 1 clinical trials with a strong safety profile. Building on these positive results, the company also announced the close and oversubscription of an initial equity round and is now positioned to raise a larger Series A round in early 2022 to enable two Phase II trials. CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases and disorders associated with Cytokine Release Syndrome, or CRS. Commonly referred to as cytokine storm and clinically known as hypercytokinemia, CRS is a potentially lethal condition associated with a range of diseases and treatments.
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year. The funding will accelerate the development of its lead drug candidate, GP1681, an investigational new drug that targets hypercytokinemia, more commonly known as “cytokine storm.”
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health (NIH) grant, the second NIH grant in a year. The funding will accelerate the development of its lead drug candidate, GP1681, an investigational new drug that targets hypercytokinemia, more commonly known as “cytokine storm.”
PITTSBURGH--(BUSINESS WIRE)-- CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 “cytokine storm,” clinically known as hypercytokinemia.
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 “cytokine storm,” clinically known as hypercytokinemia.
PITTSBURGH--(BUSINESS WIRE)--CytoAgents a clinical-stage biotechnology company focused on development of pharmaceutical products for the treatment of viral infectious diseases, including COVID-19 and the resulting cytokine storm, announced today that it has received an investment to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to treat “cytokine storm” induced by COVID-19, from the Richard King Mellon Foundation. The Program Related Investment is part of the foundation’s $25 million Pandemic Solutions Package to jump-start COVID-19 response strategies.